Treeline Biosciences has completed USD 200 million Series A+ financing led by Google Ventures, KKR and ARCH Venture Partners, bringing total funding to USD 1.1 billion since its 2021 founding by Loxo Oncology veterans Josh Bilenker and Jeff Engelman. The company initiated three Phase I trials: BCL6 degrader TLN-121 for lymphoma, broad-spectrum KRAS inhibitor TLN-372 for solid tumours, and EZH2 inhibitor TLN-254, licensed from Hengrui Pharma for up to USD 805 million.

Treeline's computational drug discovery platform targets challenging oncology targets through small molecules, protein degraders and targeted therapy antibody-drug conjugates (ADCs). The KRAS program addresses mutations beyond G12C where targeted therapies remain limited, while the BCL6 degrader aims to overcome resistance mechanisms in B-cell and T-cell lymphomas. The clinical progress demonstrates Treeline's strategy of combining internal research with strategic in-licensing to build a diversified oncology pipeline.

PharmCube's NextBiopharm® database shows Treeline Biosciences is pursuing a number of targets in oncology. Click here to request a free trial for NextBiopharm®.